Xihong Biopharma successfully concluded its debut appearance at AMWC Southeast Asia 2025, one of the most influential medical aesthetics congresses in the ASEAN region.
The registration certificate of the Class Ⅲ medical device, Poly-L-lactic Acid Microparticle Filler Injection (the “Product”), has been approved by the National Medical Products Administration of China (NMPA).
The injectable poly-L-lactic acid (PLLA) filler is classified as a Class III medical device and is currently undergoing registrational clinical trials in China...
